Investor Presentation made at the 7th Annual General Meeting

September 22, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Investor Presentation Ref: Regulation 30 of the SEBI (LODR) Regulations 2015 Please find enclosed herewith presentation made to the Shareholders of the Company at the 7th Annual General Meeting held on Tuesday, September 22, 2026. Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED Jeevan Mondkar COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl. a/a. Aarti Pharmalabs Limited Aarti Pharmalabs Limited A7nthnu Aaln Gneunaelr aGl eMneeertainlg Meeting September 2026 22nd September 2026 Corporate Scale & Operational Reach 25+ Years of Pharmaceutical Excellence 220+ Products 500+ Global Clients State-of-the-art R&D facilities 63 50+ Patents Filed Export Countries 7 Manufacturing 60 US DMF Units 2,400+ Employees 3 44 USFDA Units CEP Global 15-20% Market Share 0.32x Net Debt/Equity AA- Credit rating in Xanthine Aarti Pharmalabs Limited Company Profile & Competitive Edge Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with STANDALONE REVENUE (INR Cr) & EBITDA MARGINS (%) group turnover of INR 150+ bn (FY26) 1,798 1,771 Globally recognized manufacturer of generic API, Xanthine derivatives and a leading player in 1,511 1,502 CDMO/CMO services • 20% 24% 23% Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up 19% and commercial production Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European FY23 FY24 FY25 FY26 Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico) • GEOGRAPHICAL SALES (FY26) Strategically located in western India with proximity to ports HIGHLIGHTS Domestic, 46% International, One of the leading small Regulatory focussed Largest manufacturer of molecule CDMO/CMO operations with expertise in Xanthine Derivatives in company in India. novel chemistries; India Aarti Pharmalabs Limited Growth Journey & Value Creation 2026 • Inaugurated Tarapur(Unit 5), adding 3,600 TPA to reach a total capacity of 9,600 TPA 2024 • Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2022 • Expanded block at CSD Vapi & API In Tarapur 2025 • Acquired land in Atali for future expansion • Successfully demerged pharmaceutical business of Aarti Industries to Aarti Pharmalabs 11 Commissioned Phase 1 at Atali greenfield site with 450+ kL reactor capacity 2016 10 2023 Commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tons (MT) per month Operationalized the third R&D center 2009 • 2019 Secured USFDA approval for Dombivli Unit Successfully completed the USFDA audit at the Intermediate facility 7 • (CSD) in Vapi Successfully completed an auditC boym EmDQerMci afolizre Bdic Ballouctka mV iadte T faorra pur Unit 4 the Oncology block at Unit 4 2005 6 Enhanced Xanthine capacity to 5,000 TPA 2013 Commissioned the first API manufacturing unit in Tarapur for Regulated Markets (Unit 4) Received EUGMP approval for Bicalutamide for the Oncology block at Unit 4 1984 4 2008 Aarti Organic 3 Private Limited was incorporated Successfully completed the USFDA & EUGMP audit for Tarapur Unit 2001 Commissioned the first API manufacturing unit in Dombivli (Unit 1) and 4 started the Xanthine unit Aarti Pharmalabs Limited Standalone Multi-year Profitability Metrics Operational Revenue(INR Cr) EBITDA & Margin(INR Cr / %) PAT (INR Cr) FY23 FY23 FY23 1,511 308 20.4% 172 FY24 FY24 FY24 1,502 346 23% 201 FY25 FY25 FY25 1,771 427 24% 257 FY26 FY26 FY26 1,798 406 22.6% 176 Aarti Pharmalabs Limited Standalone Profit & Loss Statement PARTICULARS (INR Mn) FY26 FY25 Y-O-Y Operational Revenue 17,976 17,714 1.5% Operating Expenses 13,915 13,449 3.5% EBITDA 4,061 4,265 (4.8)% EBITDA Margin (%) 22.59% 24.08% (149) Bps Depreciation and Amortisation 1,043 791 31.9% Finance costs 469 256 83.2% Foreign Exchange (Gain)/Loss 332 (17) NA Other Income 153 128 19.5% PBT before Exceptional Items 2,370 3,363 (29.5)% Exceptional Items 28 - NA PBT 2,342 3,363 (30.4)% Tax Expense 580 790 (26.6)% PAT 1,762 2,573 (31.5)% PAT Margin (%) 9.80% 14.53% (473) Bps Other Comprehensive Income (39) (51) (23.5)% Total Comprehensive Income 1,723 2,522 (31.7)% Diluted EPS (INR) 19.42 28.38 (31.6)% # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous year figures restated accordingly. 6 Aarti Pharmalabs Limited Consolidated Profit & Loss Statement PARTICULARS (INR Mn) FY26* FY25 Y-O-Y Operational Revenue 18,194 21,151 (14.0)% Operating Expenses 14,170 16,507 (14.2)% EBITDA 4,024 4,644 (13.4)% EBITDA Margin (%) 22.12% 21.96% 16 Bps Depreciation and Amortisation 1,043 869 20.0% Finance costs 469 269 74.3% Foreign Exchange (Gain)/Loss 332 (17) NA Other Income 97 84 15.5% PBT before Joint Venture & Exceptional Items 2,277 3,607 (36.9)% Exceptional Items (Net of Tax Expenses) 28 - NA PBT before Joint Venture 2,249 3,607 (37.6)% Share of JV 80 - NA PBT 2,329 3,607 (35.4)% Tax Expense 582 883 (34.1)% PAT 1,747 2,724 (35.9)% PAT Margin (%) 9.60% 12.88% (328) Bps Other Comprehensive Income (62) (98) (36.7)% Total Comprehensive Income 1,685 2,626 (35.8)% Diluted EPS (INR) 19.25 30.04 (35.9)% # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous year figures restated accordingly. *Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods. 7 Aarti Pharmalabs Limited Recent Investments Greenfield Capex – Atali Project (Gujarat) Brownfield Capex – Tarapur (Maharashtra) Estimated Investment INR 400 crores Estimated Investment INR 210 crores Capacity ~450 KL (Block 1) Proposed Capacity 9,000 MTPA Land Available 80 acres Current Utilization 6,000 MTPA Timeline Operationalized in Q1FY27 Timeline ~80% capacity operationalized by Q4FY26 Product Focus Xanthine Derivatives Product Focus Intermediates and CDMO/CMO Strategic Rationale Strategic Rationale • To have a growth engine for CDMO / CMO segment with large • Beverage sales are predominantly driven by long-standing client expansion potential relationships, ensuring a consistent revenue stream • Enhance backward integration with expanded intermediates capacity • With enhanced capacity, there’s aspiration to grab larger wallet share with beverage customers Future Potential • Increase share in pharmaceutical grade Xanthine derivatives to • Atali site is scalable up to 8-10x of Phase 1 capacity expand margins Aarti Pharmalabs Limited Future Outlook FY26 CAPEX reached ~ INR 400 cr; FY27 outlook expected at similar levels Targeting 15-18% Initiating R&D investment in FY27 towards TIDES (Peptides Revenue & EBITDA CAGR & Oligonucleotides) to expand portfolio capabilities. Over the Next 3-4 Years Announced capex for Atali Block 2 for specific CDMO / CMO projects; Groundbreaking planned in Q3FY27 Aarti Pharmalabs Limited THANK YOU AARTI PHARMALABS LIMITED